Comparative Pharmacology
Head-to-head clinical analysis: PEPCID versus ZANTAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID versus ZANTAC.
PEPCID vs ZANTAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion by inhibiting cyclic AMP generation.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
20 mg orally twice daily or 40 mg orally once daily at bedtime for duodenal ulcer; 40 mg orally once daily at bedtime for gastric ulcer; 20 mg orally once daily for GERD; 20 mg orally twice daily for erosive esophagitis; 20 mg intravenously every 12 hours for hospitalized patients with pathological hypersecretory conditions.
150 mg orally twice daily or 50 mg intravenously every 6-8 hours. Alternatively, 300 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in normal renal function; prolonged to 8-10 hours in moderate renal impairment (CrCl 10-50 mL/min) and 15-20 hours in severe impairment (CrCl <10 mL/min); no significant change in hepatic impairment.
2.5-3 hours (normal renal function); prolonged to 4-5 hours in elderly and up to 20 hours in severe renal impairment (CrCl < 30 mL/min).
Renal: ~65-70% unchanged via tubular secretion (active) and glomerular filtration; hepatic metabolism (S-oxidation) ~30%; fecal: <5%.
Renal: 30% unchanged (tubular secretion); hepatic metabolism to N-oxide, S-oxide, and desmethyl ranitidine; biliary/fecal: minimal.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist